These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 31747516

  • 1. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
    Zhou H, Bai L, Xu R, Zhao Y, Chen J, McEachern D, Chinnaswamy K, Wen B, Dai L, Kumar P, Yang CY, Liu Z, Wang M, Liu L, Meagher JL, Yi H, Sun D, Stuckey JA, Wang S.
    J Med Chem; 2019 Dec 26; 62(24):11280-11300. PubMed ID: 31747516
    [Abstract] [Full Text] [Related]

  • 2. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.
    Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, Chen J, Yang CY, Liu Z, Wang M, Liu L, Jiang H, Wen B, Kumar P, Meagher JL, Sun D, Stuckey JA, Wang S.
    Cancer Cell; 2019 Nov 11; 36(5):498-511.e17. PubMed ID: 31715132
    [Abstract] [Full Text] [Related]

  • 3. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
    Huang Q, Zhong Y, Li B, Ouyang S, Deng L, Mo J, Shi S, Lv N, Wu R, Liu P, Hu W, Zhang X, Wang Y.
    Eur J Med Chem; 2021 Oct 05; 221():113525. PubMed ID: 34000483
    [Abstract] [Full Text] [Related]

  • 4. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
    Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S.
    J Med Chem; 2018 Jan 25; 61(2):462-481. PubMed ID: 28339196
    [Abstract] [Full Text] [Related]

  • 5. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
    Li Y, Yang J, Aguilar A, McEachern D, Przybranowski S, Liu L, Yang CY, Wang M, Han X, Wang S.
    J Med Chem; 2019 Jan 24; 62(2):448-466. PubMed ID: 30525597
    [Abstract] [Full Text] [Related]

  • 6. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X, Bai L, Xu Y, Wang J, Lu H.
    Biochem Biophys Res Commun; 2020 Jan 22; 521(4):833-839. PubMed ID: 31708096
    [Abstract] [Full Text] [Related]

  • 7. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
    Han X, Zhao L, Xiang W, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Wang L, Matvekas A, Wen B, Sun D, Wang S.
    J Med Chem; 2021 Sep 09; 64(17):12831-12854. PubMed ID: 34431670
    [Abstract] [Full Text] [Related]

  • 8. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
    Qin C, Hu Y, Zhou B, Fernandez-Salas E, Yang CY, Liu L, McEachern D, Przybranowski S, Wang M, Stuckey J, Meagher J, Bai L, Chen Z, Lin M, Yang J, Ziazadeh DN, Xu F, Hu J, Xiang W, Huang L, Li S, Wen B, Sun D, Wang S.
    J Med Chem; 2018 Aug 09; 61(15):6685-6704. PubMed ID: 30019901
    [Abstract] [Full Text] [Related]

  • 9. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
    Wu T, Hu J, Zhao X, Zhang C, Dong R, Hu Q, Xu H, Shen H, Zhang X, Zhang Y, Lin B, Wu X, Xiang Q, Xu Y.
    J Med Chem; 2024 Jun 13; 67(11):9194-9213. PubMed ID: 38829718
    [Abstract] [Full Text] [Related]

  • 10. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W, Wang Q, Ran K, Ren J, Shi Y, Yu L.
    Bioorg Chem; 2021 Oct 13; 115():105238. PubMed ID: 34390970
    [Abstract] [Full Text] [Related]

  • 11. SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.
    Zhou H, Bai L, Xu R, McEachern D, Chinnaswamy K, Li R, Wen B, Wang M, Yang CY, Meagher JL, Sun D, Stuckey JA, Wang S.
    ACS Med Chem Lett; 2021 Jun 10; 12(6):996-1004. PubMed ID: 34141084
    [Abstract] [Full Text] [Related]

  • 12. Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.
    Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, Kirchhoff PD, Wen B, Sun D, Stuckey JA, Wang S.
    J Med Chem; 2023 Feb 23; 66(4):2717-2743. PubMed ID: 36735833
    [Abstract] [Full Text] [Related]

  • 13. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.
    Wang C, Wang M, Wang Y, Rej RK, Aguilar A, Xu T, Bai L, Tošović J, McEachern D, Li Q, Sarkari F, Wen B, Sun D, Wang S.
    J Med Chem; 2024 Aug 22; 67(16):14125-14154. PubMed ID: 39132814
    [Abstract] [Full Text] [Related]

  • 14. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
    Hu J, Hu B, Wang M, Xu F, Miao B, Yang CY, Wang M, Liu Z, Hayes DF, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.
    J Med Chem; 2019 Feb 14; 62(3):1420-1442. PubMed ID: 30990042
    [Abstract] [Full Text] [Related]

  • 15. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
    Godse P, Kumar P, Yewalkar N, Deore V, Lohar M, Mundada R, Padgaonkar A, Manohar S, Joshi A, Bhatia D, Desai N, Damre A, Bhonde M, Joshi K, Sharma R, Kumar S.
    Anticancer Agents Med Chem; 2013 Nov 14; 13(9):1460-6. PubMed ID: 24102269
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer.
    Li H, Wang L, Cao F, Yu D, Yang J, Yu X, Dong J, Qin JJ, Guan X.
    Front Pharmacol; 2022 Nov 14; 13():944455. PubMed ID: 36034876
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.